AGN — Algernon Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- CA$2.81m
- CA$2.74m
Annual cashflow statement for Algernon Pharmaceuticals, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.9 | -8.54 | -7.73 | -6.05 | -6.78 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -0.008 | 3 | 0.509 | 0.522 | 2.91 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.094 | -1.07 | -0.598 | 2.58 | 1.27 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.78 | -6.61 | -7.82 | -2.91 | -2.55 |
| Capital Expenditures | -0.066 | -0.1 | -0.124 | -0.145 | -0.059 |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.156 | 0 | — | — | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | 0.09 | -0.1 | -0.124 | -0.145 | -0.059 |
| Financing Cash Flow Items | — | — | -0.312 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.648 | 12.6 | 4.25 | 2.06 | 1.33 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.04 | 5.91 | -3.71 | -1 | -1.28 |